文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

接受V-V ECMO的ARDS患者肺动脉血流动力学早期轨迹:关键决定因素与预后影响

Early trajectories of pulmonary hemodynamics in ARDS patients undergoing V-V ECMO: key determinants and prognostic impact.
PubMed 文献 · Crit Care · 2026-03-02
一句话结论接受V-V ECMO的ARDS患者中,早期mPAP上升轨迹(而非首日mPAP值)独立预测住院死亡率升高(校正OR 1.89/1-mmHg/天)。

该回顾性观察研究纳入2003至2024年一家三级转诊中心240例连续V-V ECMO成人ARDS患者,其中225例置有肺动脉导管者被分析。ECMO期间mPAP中位数27 mmHg(23–32),91%的测量值超过20 mmHg。首日mPAP与住院死亡率无关,而ECMO前5天mPAP轨迹(患者特异性每日斜率)独立与死亡率相关(校正OR 1.89每1-mmHg/天增加,95%CI 1.33–2.77,p<0.001)。结论提示系列肺动脉压力监测可能提供预后信息并帮助指导ECMO支持的ARDS患者的肺血流动力学管理。

要点

  • 在V-V ECMO支持的ARDS患者中,首日mPAP与住院死亡率无显著关联,不能仅凭初始肺动脉压力判断预后。
  • ECMO前5天mPAP每日上升轨迹独立预测住院死亡率升高:校正OR 1.89每1-mmHg/天增加(95%CI 1.33–2.77,p<0.001)。
  • ECMO期间肺动脉高压高发:mPAP中位数27 mmHg(23–32),91%的测量值超过20 mmHg。
  • 较高mPAP的独立决定因素包括肺内分流分数、较低静脉pH、较高肺动脉闭塞压、较高PEEP、较低呼吸系统顺应性和较长ECMO时长。
  • 较高静脉氧分压和混合静脉血氧饱和度与较低mPAP相关。

适用人群与场景

  • 2003至2024年一家三级转诊中心接受V-V ECMO的成人ARDS患者,仅纳入置有肺动脉导管监测者,共225例分析。

研究设计与关键结果

  • 回顾性观察研究,240例连续V-V ECMO患者中225例置有肺动脉导管者被分析;中位年龄51岁,33%为女性。
  • ECMO期间mPAP中位数27 mmHg(23–32),91%的测量值超过20 mmHg。
  • 首日mPAP与住院死亡率无显著关联。
  • ECMO前5天mPAP轨迹(患者特异性每日斜率)独立与住院死亡率相关:校正OR 1.89每1-mmHg/天增加(95%CI 1.33–2.77,p<0.001)。
  • 较高mPAP的独立决定因素包括肺内分流分数、较低静脉pH、较高肺动脉闭塞压、较高PEEP、较低呼吸系统顺应性和较长ECMO时长;较高静脉氧分压和混合静脉血氧饱和度与较低mPAP相关。

证据类型、等级与局限

  • 证据类型:回顾性观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,系列肺动脉压力监测可能提供预后信息并帮助指导ECMO支持的ARDS患者的肺血流动力学管理。
  • 首日mPAP值不宜单独用于预后判断;ECMO前5天mPAP的每日上升轨迹与住院死亡率升高独立相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Pulmonary hypertension (PH) frequently complicates acute respiratory distress syndrome (ARDS) and contributes to right ventricular dysfunction and mortality. Veno-venous extracorporeal membrane oxygenation (V-V ECMO) may attenuate PH through improved gas exchange, yet pulmonary pressures often remain elevated. Data on the determinants and prognostic impact of PH in ECMO-supported ARDS are limited. METHODS: We performed a retrospective observational study of adult ARDS patients receiving V-V ECMO at a tertiary referral center between 2003 and 2024. Only patients monitored with a pulmonary artery catheter were included. Daily hemodynamic, ventilatory, and gas exchange data were prospectively collected. Determinants of mean pulmonary artery pressure (mPAP) were analyzed using a linear mixed-effects model. The association of (1) mPAP on the first day of ECMO and (2) the mPAP trajectory over the first 5 ECMO days—expressed as the patient-specific daily slope—with hospital mortality was assessed using logistic regression before and after adjustment for confounders. RESULTS: Among 240 consecutive V-V ECMO patients, 225 had a pulmonary artery catheter and were analyzed. Median age was 51 years, 33% were female. The median mPAP during ECMO was 27 mmHg [23–32], with 91% of measurements exceeding 20 mmHg. Independent determinants of higher mPAP included intrapulmonary shunt fraction, lower venous pH, higher pulmonary artery occlusion pressure, increased PEEP, reduced respiratory system compliance, and longer ECMO duration. In contrast, higher venous partial pressure of oxygen and mixed venous oxygen saturation were associated with lower mPAP. mPAP on the first day of ECMO was not associated with hospital mortality. In contrast, the trajectory of mPAP during the first 5 days was independently associated with mortality (adjusted OR 1.89 per 1-mmHg/day increase, 95% CI 1.33–2.77, p < 0.001). CONCLUSIONS: Pulmonary hypertension is highly prevalent in ARDS patients on V-V ECMO and reflects underlying disease severity. Early upward trajectories in mPAP, rather than the initial mPAP value, independently predicted higher mortality. Serial pulmonary pressure monitoring may provide relevant prognostic information and help guide management of pulmonary hemodynamics in ECMO-supported ARDS.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Giani M, Bombino M, Ravasi M, et al. Early trajectories of pulmonary hemodynamics in ARDS patients undergoing V-V ECMO: key determinants and prognostic impact. Crit Care. 2026. PMID: 41772666. doi:10.1186/s13054-026-05855-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。